 |
| For information about ordering RotaTeq, Merck vaccines, and other services, visit www.MerckVaccines.com. Or, call the Merck Vaccine Customer Center at 1-877-VAX-MERCK (1-877-829-6372) Monday through Friday, 8:00 AM to 7:00 PM, ET. |
 |
| This information is intended to help your office: |
|
•
|
Determine your patients' managed care coverage |
|
•
|
Access commonly used codes that may apply to private payer reimbursement claims |
| |
| For reimbursement questions for RotaTeq and other Merck vaccines, please call the Merck Vaccine Reimbursement Support Center at 1-800-REIMBVAX (1-800-734-6282). |
| |
|
|
90680
|
Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use |
| 90467 |
Immunization administration under age 8 years (includes intranasal or oral routes of administration) when the physician counsels the patient/family; first administration (single or combination vaccine/toxoid), per day. (Do not report 90467 in conjunction with 90465) |
|
90468
|
Each additional administration (single or combination vaccine/toxoid), per day (List separately in addition to code for primary procedure). (Use 90468 in conjunction with 90465 or 90467) |
| 90473 |
Immunization administration by intranasal or oral route; one vaccine (single/or combination vaccine/toxoid). (Do not report 90473 in conjunction with 90471) |
|
90474
|
Each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure). (Use 90474 in conjunction with 90471 or 90473) |
| V04.89 |
Need for prophylactic vaccination and inoculation against certain viral diseases; other viral disease |
|
V05.8
|
Need for prophylactic vaccination and inoculation against a single disease; other specified disease |
|
| |
| This resource is not intended to be conclusive or exhaustive as to what codes may be appropriate. You are solely responsible for determining the appropriate codes. Diagnosis codes should be selected only by a health care professional. Consult the ICD-9-CM 2006 manual to check the appropriateness of a particular code and for information on additional codes. Merck does not warrant or guarantee the timeliness or appropriateness of this information for your particular use and cannot guarantee that use of this information will result in reimbursement. Merck is not responsible for any action you take in billing for a Merck vaccine. |
| |
| • |
RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. |
| • |
The first dose of RotaTeq should be administered between 6 and 12 weeks of age. |
| • |
RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to any component of the vaccine. |
| • |
No safety or efficacy data are available for the administration of RotaTeq to infants who are potentially immunocompromised, or with a history of gastrointestinal disorders. |
| • |
Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts. |
| • |
Over 71,000 infants were evaluated in 3 placebo-controlled clinical trials. Serious adverse events occurred in 2.4% of recipients of RotaTeq when compared to 2.6% of placebo recipients within the 42-day period of a dose of RotaTeq. Hematochezia reported as a serious adverse event for RotaTeq compared to placebo was <0.1% vs <0.1%. The most frequently reported serious adverse events for RotaTeq compared to placebo were bronchiolitis (0.6% vs 0.7%), gastroenteritis (0.2% vs 0.3%), pneumonia (0.2% vs 0.2%), fever (0.1% vs 0.1%), and urinary tract infection (0.1% vs 0.1%). |
| • |
In a subset of more than 11,000 infants in these trials, the presence of adverse events was reported for 42 days after each dose. Fever was observed at similar rates in vaccine and placebo recipients (42.6% vs 42.8%). Adverse events that occurred at a statistically higher incidence within 42 days of any dose among recipients of RotaTeq as compared with placebo recipients were diarrhea (24.1% vs 21.3%), vomiting (15.2% vs 13.6%), otitis media (14.5% vs 13.0%), nasopharyngitis (6.9% vs 5.8%), and bronchospasm (1.1% vs 0.7%). |
| • |
In post-marketing experience, cases of intussusception and Kawasaki disease have been reported in infants who have received RotaTeq. |
| • |
RotaTeq may not protect all vaccine recipients against rotavirus. |
| • |
Before administering RotaTeq, please read the Prescribing Information and Patient Product Information. |
|
| |
a Current Procedural Terminology © 2007 American Medical Association. All rights reserved.
b Physicians ICD-9-CM © 2006 American Medical Association. All rights reserved. |
| |
|
Previous topic: < Welcomed Convenience |
Next topic: Patient Education > |
|
|
|
|
|
|
|
 |
|
| Educate your patients about rotavirus and RotaTeq. |
|
|
|
|
|
|
|
